Article Details

Pyrazoline containing molecules as multifunctional agents in alzheimer’s disease

Khambete M.a, Murumkar P.b,c, Kumar A.c, Darreh-Shori T.c, De S.a, Yadav M. R.b and Degani M. S.a*

a Department of Pharmaceutical Sciences and Technology, Institute of chemical technology, Matunga (e), Mumbai 400019, Maharashtra, India <

b Faculty of Pharmacy, the Maharaja Sayajirao University of Baroda, Vadodara - 390 001, Gujurat, India

c Karolinska Institute, Center for Alzheimer Research, Department of Neurobiology, care-Sciences and Society, Division of clinical Geriatric, NeO, Blickagangen 16, 141 52 Huddinge, Sweden 

* For correspondence: email - ms.degani@ictmumbai.edu.in, msdegani@gmail.com


ABSTRACT

Alzheimer’s disease (AD) is a progressive, neurodegenerative disease which is caused mainly due to accumulation of an aberrant protein known as β-amyloid in the form of senile plaques. However, over the past few years, network biology studies have indicated that classical “one drug-one target” hypothesis may not work in diseases such as AD where the biochemical disease mechanisms are intricately interconnected. therefore, multifunctional molecules which can modulate several targets could be the key towards finding the therapeutics for this debilitating disorder. Keeping this in mind, several pyrazoline containing molecules with promising Aβ aggregation inhibition potential were explored further against key targets involved in AD, such as cholinesterases, oxidative stress and advanced glycation end products (AGe). Some potential multifunctional molecules were identified as a result of this work.

 

Year 2019 | Volume No. 56 | Issue No.10 | Page No. 22-25
Recent Issue
Current Issue
October 2019
Quick Contact